Prothena Corp. (NASDAQ: PRTA) reported Q2 EPS of ($2.34), $1.12 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $6.95 million.

2025 Financial Guidance

The Company continues to expect its full year net cash used in operating and investing activities to be $170 to $178 million and to end the year with approximately $298 million (midpoint) in cash, cash equivalents, and restricted cash. The estimated full year 2025 net cash used from operating and investing activities is primarily driven by an estimated net loss of $240 to $248 million, which includes an estimated $36 million of non-cash share-based compensation expense and a $44.9 million non-cash income tax expense to book a full valuation allowance against its federal deferred tax assets.

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.